Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A meta-analysis in 73 913 patients

Journal of Hypertension

Volumn 29, Issue 7, 2011, Pages 1253-1269

  Reboldi, Gianpaolo ^a   Gentile, Giorgio ^a   Angeli, Fabio ^b   Ambrosio, Giuseppe ^a   Mancia, Giuseppe ^c   Verdecchia, Paolo ^d  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Hospital 'Santa Maria della Misericordia'   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d Hospital of Assisi   (Italy)

Author keywords

cardiovascular risk; diabetes; hypertension; meta analysis; myocardial infarction; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; FOSINOPRIL; IMIDAPRIL; LISINOPRIL; LOSARTAN; METOPROLOL; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TASOSARTAN; TELMISARTAN; TEMOCAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPOTENSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 79958769725     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283469976     Document Type: Review

References (65)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-444. (Pubitemid 23046633)
2. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (procam) study. Circulation 2002; 105:310-315. (Pubitemid 34106178)
3. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in us adults with cardiovascular disease comorbidities in 2003-2004. Arch Intern Med 2007; 167:2431-2436. (Pubitemid 350254901)
4. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
5. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the american heart association and the american diabetes association. Circulation 2007; 115:114-126. (Pubitemid 46058619)
6. ADA. Standards of medical care in diabetes: 2010. Diabetes Care 2010; 33(Suppl 1):S11-S61.
7. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
8. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of european guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
9. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
10. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in medline. J Am Med Inform Assoc 1994; 1:447-458.
11. Gré goire G, Derderian F, Le Lorier J. Selecting the language of the publications included in a meta-analysis: is there a tower of babel bias? J Clin Epidemiol 1995; 48:159-163.
12. McAuley L, Pham B, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in metaanalyses? Lancet 2000; 356:1228-1231.
13. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic hypertension in the elderly program cooperative research group. JAMA 1996; 276:1886-1892. (Pubitemid 26419185)
14. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (convince) trial. JAMA 2003; 289:2073-2082. (Pubitemid 37430209)
15. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and niddm. Diabetes Care 1998; 21:597-603. (Pubitemid 28172941)
16. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: Ukpds 39. BMJ 1998; 317:713-720.
17. Gasowski J, Staessen JA, Celis H, Fagard RH, Thijs L, Birkenhager WH, et al. Systolic hypertension in Europe (syst-eur) trial phase 2: objectives, protocol, and initial progress. J Hum Hypertension 1999; 13:135-145. (Pubitemid 29101297)
18. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2): B54-B64. (Pubitemid 30185779)
19. HOPE Study Group. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the hope study and micro-hope substudy. Heart outcomes prevention evaluation study investigators. Lancet 2000; 355:253-259.
20. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356:359-365. (Pubitemid 30487491)
21. O'Hare P, Bilbous R, Mitchell T, CJ OC, Viberti GC. Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. Diabetes Care 2000; 23:1823-1829.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
23. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ace inhibitor compared with a diuretic/betablocker- based treatment regimen: a subanalysis of the captopril prevention project. Diabetes Care 2001; 24:2091-2096. (Pubitemid 33716527)
24. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (life): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
25. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61:1086-1097. (Pubitemid 34175478)
26. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003; 361:1077-1083. (Pubitemid 36369559)
27. Bath P, Chalmers J, Powers W, Beilin L, Davis S, Lenfant C, et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21:665-672.
28. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236. (Pubitemid 39473160)
29. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961. (Pubitemid 39447136)
30. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, Woodward M. Reductions in the risks of recurrent stroke in patients with and without diabetes: the progress trial. Blood Press 2004; 13:7-13. (Pubitemid 38455840)
31. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Menard J. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the diabhycar study). BMJ 2004; 328:495.
32. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, et al. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-b (JMIC-b) subgroup analysis. Hypertens Res 2004; 27:449-456. (Pubitemid 39157546)
33. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the europa study: results from the persuade substudy. Eur Heart J 2005; 26:1369-1378. (Pubitemid 41373513)
34. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, et al. Efficacy, safety and tolerability of metoprolol cr/xl in patients with diabetes and chronic heart failure: experiences from merit-hf. Am Heart J 2005; 149:159-167. (Pubitemid 40126504)
35. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223. (Pubitemid 40138015)
36. Schrader J, Hammersen F, Luders S, Kulschewski A, Plate K, Berger J, et al. Morbidity and mortality after stroke in patients with diabetes-subgroup analysis from the moses-study. J Clin Basic Cardiol 2006; 9 (Suppl 1): 2-5.
37. Danchin N, Wagener G, Kirwan B, De Brouwer S, Lubsen J, Poole-Wilson P. Efficacy and safety of long-acting nifedipine in patients with symptomatic stable angina pectoris with and without diabetes: the action trial. Doctoral thesis. http://publishing.eur.nl/ir/repub/asset/10627/ 071026-Wagener,Gilbert. pdf. 2007.
38. Chalmers J, Kengne AP, Joshi R, Perkovic V, Patel A. New insights from advance. J Hypertens Suppl 2007; 25:S23-30.
39. Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, et al. The anglo-scandinavian cardiac outcomes trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008; 26:2103-2111.
40. Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial. Diabetes Care 2008; 31:1007-1014.
41. ACCORD SG. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensinconverting- enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329:1456-1462. (Pubitemid 23335891)
43. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994; 154:2154-2160. (Pubitemid 24317261)
44. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (solvd) trials and registry. Am J Cardiol 1996; 77:1017-1020. (Pubitemid 26158096)
45. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941-1951. (Pubitemid 39447135)
46. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Oxford: Wiley-Blackwell; 2008.
47. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The prisma statement. BMJ 2009; 339:b2535.
48. Sutton A, Abrams K, Jones D. Methods for meta-analysis in medical research. Wiley Series in Probability and Statistics. Chichester, John Wiley & Sons Ltd.; 2000.
49. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-1573. (Pubitemid 34746063)
50. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23:1663-1682. (Pubitemid 38765338)
51. Woodward M. Epidemiology: study design and data analysis. Boca Raton: Chapman & Hall/CRC; 2005.
52. Lau J, Schmid CH, Chalmers TC. Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol 1995; 48:45-57; discussion 59-60.
53. Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials 1997; 18:580-593. (Pubitemid 27520846)
54. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 2008; 61:64-75. (Pubitemid 350245732)
55. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774. (Pubitemid 20106689)
56. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838. (Pubitemid 20113741)
57. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
58. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28:385-407. (Pubitemid 41014801)
59. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419. (Pubitemid 40973424)
60. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study. J Hypertens 2009; 27:1360-1369.
61. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373:1765-1772.
62. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288-2298.
63. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371:1800-1809. (Pubitemid 351697956)
64. Lago RM, Nesto RW. Type 2 diabetes and coronary heart disease: focus on myocardial infarction. Curr Diab Rep 2009; 9:73-78.
65. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United kingdom prospective diabetes study (ukpds: 23). BMJ 1998; 316:823-828. (Pubitemid 28112428)